Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC50s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively.
ln Vitro |
mRNA luteolin 7-O-glucuronide (0-50 μM, 2 hours) can inhibit the activation of NF-κB, p38, and JNK in LPS-stimulated RAW 264.7 macrophages. It also inhibits LPS-stimulated NO production and regulates mediators (COX-2, IL-6, IL-1β, and TNF-α) in these macrophages [2].
|
---|---|
ln Vivo |
In a mouse cortical model of sleep reactive behavior, luteolin 7-O-glucuronide (0.3–3 mg/kg, lateral, once daily for 5 days) ameliorates depressive-like and stress-like symptoms in the tail suspension test and forced swim test [3].
|
Cell Assay |
Western Blot Analysis[2]
Cell Types: LPS stimulated RAW 264.7 macrophages Tested Concentrations: 0-50 μM Incubation Duration: 2 hrs (hours) Experimental Results: Inhibition of IκB phosphorylation and degradation. Inhibits the phosphorylation of p38 and JNK. |
Animal Protocol |
Animal/Disease Models: Mouse sleep deprivation model [3]
Doses: 0.3-3 mg/kg Route of Administration: Orally, one time/day for 5 days Experimental Results: Reduce the increased immobility time of sleep-deprived mice. Reduce elevated plasma corticosterone levels. diminished TNF-α and IL-1β levels and increased BDNF mRNA expression in the hippocampus of sleep-deprived mice. |
References |
[1]. Crascì L, et al. Correlating In Vitro Target-Oriented Screening and Docking: Inhibition of Matrix Metalloproteinases Activities by Flavonoids. Planta Med. 2017 Jul;83(11):901-911.
[2]. Cho YC, et al. Anti-Inflammatory and Anti-Oxidative Effects of luteolin-7-O-glucuronide in LPS-Stimulated Murine Macrophages through TAK1 Inhibition and Nrf2 Activation. Int J Mol Sci. 2020 Mar 16;21(6):2007. [3]. Ryu D, et al. Luteolin-7-O-Glucuronide Improves Depression-like and Stress Coping Behaviors in Sleep Deprivation Stress Model by Activation of the BDNF Signaling. Nutrients. 2022 Aug 12;14(16):3314. |
Molecular Formula |
C₂₁H₁₈O₁₂
|
---|---|
Molecular Weight |
462.36
|
CAS # |
29741-10-4
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O[]([]([C@@H]([C@@H](C(O)=O)O1)O)O)[C@@H]1OC2=CC(O)=C3C(C=C(C4=CC=C(O)C(O)=C4)OC3=C2)=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~125 mg/mL (~270.35 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 5 mg/mL (10.81 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: 15.71 mg/mL (33.98 mM) in 0.5% MC 0.5% Tween-80 (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1628 mL | 10.8141 mL | 21.6282 mL | |
5 mM | 0.4326 mL | 2.1628 mL | 4.3256 mL | |
10 mM | 0.2163 mL | 1.0814 mL | 2.1628 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.